Abstract In contrast to deoxyribose or arabinose containing nucleoside analogs that are currently established for cancer therapeutics, 8-chloro-adenosine (8-Cl-Ado) possesses a ribose sugar. This unique nucleoside analog is RNA-directed and is in a phase I clinical trial for hematological malignancies. RNA-directed therapies are effective for the treatment of many malignancies as their activities are primarily aimed at short-lived transcripts, which are typically encoded by genes that promote the growth and survival of tumor cells such as cyclin E in breast cancer. Based on this, we hypothesized that 8-ClAdo, a transcription inhibitor, will be effective for the treatment of breast cancer cells. The metabolism of 8-ClAdo and the effect on ATP in the breast cancer cell lines MCF-7 and BT-474 were measured using HPLC analysis. In these cells, 8-Cl-Ado was effectively taken up, converted to its cytotoxic metabolite, 8-Cl-ATP, and depleted the endogenous ATP levels. This in turn led to an inhibition of RNA synthesis. The RNA synthesis inhibition was associated with a depletion of cyclin E expression, which is indicative of a diminished tumorigenic phenotype. The final outcome of 8-Cl-Ado treatment of the breast cancer cells was growth inhibition due to an induction of apoptosis and a loss of clonogenic survival. These results indicate that 8-Cl-Ado, which is currently in clinic for hematological malignancies, may be an effective agent for the treatment of breast cancer.
Introduction
Transcription is an emerging target for cancer therapeutics [1, 2] . Though RNA-directed agents globally affect RNA synthesis, their activities are most effective against transcripts with high turn-over rates. These short-lived transcripts are typically encoded by oncogenes as well as by regulators of other key processes such as cell proliferation, angiogenesis, and cell survival [3, 4] . Therefore, treatments that impede mRNA synthesis would be expected to selectively hinder their expression and, furthermore, be detrimental to neoplastic cells that are dependent on or addicted to the activity of these genes for their tumorigenicity [5] [6] [7] [8] .
Though many chemotherapeutic agents currently used in the clinic have some inhibitory effects on transcription [2] , it is a primary mechanism of action for the cdk7/9 inhibitors flavopiridol, Seliciclib, and SNS-032, as they prevent transcription initiation and elongation by inhibiting the phosphorylation of RNA Pol II on serine residues. In chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and multiple myeloma (MM), this results in the depletion of the short-lived survival factors MCL-1, XIAP, and MET, which are crucial for the survival of these cells [9] [10] [11] [12] [13] [14] [15] . Furthermore, these agents have shown potent cytotoxic activity during preclinical investigations and encouraging results in clinical trials on these malignancies [10, 16] .
The ribonucleoside analog, 8-chloro-adenosine (8-ClAdo), exhibits a strong potential for use as an effective, RNA-directed therapeutic agent and is currently in a Phase I clinical trial for the treatment of CLL. 8-Cl-Ado is cytotoxic to primary CLL cells [17] , as well as to glioma [18] [19] [20] , MM [21] [22] [23] , myeloid leukemia [24] , colon [25] , and lung [26] cancer cell lines. We have shown that 8-ClAdo cytotoxicity is contingent on its intracellular phosphorylation to 8-Cl-AMP by adenosine kinase [21] , which is followed by the formation of 8-Cl-ATP. Due to adenosine kinase's high specific activity and substantial substrate specificity for 8-Cl-Ado, in hematopoietic cells, 8-Cl-ATP accumulates to near millimolar levels [17, 21] . Parallel to 8-Cl-ATP accumulation, the endogenous ATP pool decreases, resulting in a high ratio of 8-Cl-ATP to ATP. The net effect of this is a decline in RNA synthesis. The mechanism by which the analog inhibits RNA synthesis is via incorporation of 8-Cl-ATP by RNA Pol into RNA. Of the various species of RNA, mRNA synthesis is inhibited the most due to the preferential incorporation by RNA Pol II into the body of the mRNA and the likely detrimental effects on poly(A) polymerase [27, 28] . These actions lead to premature termination of transcription [27] . Furthermore, in both primary CLL cells and MM cells, we showed that 8-Cl-Ado induces apoptosis by diminishing the expression of genes consequential for their survival [17, 29] .
In breast cancer, numerous studies have established a critical role that cyclin E plays in tumorigenesis, progression, and chemotherapeutic resistance, in particular, resistance to hormone-directed therapies. First, while in normal cells cyclin E in conjunction with CDK2 regulates the G 1 to S phase transition of the cell cycle, deregulation of cyclin E by various alterations such as the generation of lowmolecular-weight (LMW) isoforms, gene amplification [30, 31] and mutations of its ubiquitin ligase, CDC4 [32] , has been directly implicated in breast cancer tumorigenesis. Second, deregulation of this cyclin has been shown to cause aberrant execution of mitosis [33] , leads to premature degradation of cyclin B, shortens the G 2 /M phase of the cell cycle, interferes with prereplication complex assembly, increases centrosome numbers, and induces chromosome instability, generating aneuploidy and multinucleated cells [34] [35] [36] . Third, high expression levels of cyclin E isoforms have not only been associated with a poorer prognosis [37, 38] , but it has also been suggested to be the single most significant predictor of survival in node-negative breast tumors [39] . Fourth, tumor-specific LMW isoforms-CDK2 complexes exhibit higher kinase activity when compared to full-length cyclin E-CDK2 [40] . Fifth, due to their strong binding ability and resistance to the actions of the CDK inhibitors, p21 and p27, the LMW isoforms may sequester these inhibitors away from full-length cyclin E [34, 41] . Finally, overexpression of cyclin E in the mammary epithelial cells of transgenic mice induces tumor formation and metastasis, both of which are markedly increased in mice specifically expressing the LMW isoforms [42] . Collectively, these data demonstrate the strong role of cyclin E in breast cancer tumorigenicity and underscore the desperate need for agents that are able to target cyclin E expression for the treatment of this disease.
Cyclin E mRNA and protein are known to have a very short half-life (t C 30 min) [30, 43] ; thus, is a potential target of transcription inhibitors. In the present study, we have examined the metabolism and mechanism of action of 8-Cl-Ado in breast cancer cell lines and assessed its ability to inhibit the expression of the cyclin E gene, CCNE1.
Materials and methods

Materials
8-Cl-Ado was obtained from Dr. V. Rao at the Drug Development Branch of the National Cancer Institute. [5, 6- 3 H]uridine (*40 Ci/mM, 1 mCi/ml) was purchased from Moravek Biochemicals (Brea, CA). All of the other chemicals were of reagent grade. Primary antibodies used were rabbit polyclonal antibodies to BCL-2, MCL-1 (Santa Cruz Biotechnology, Santa Cruz, CA), and survivin (R&D Systems Inc., Minneapolis, MN) and mouse monoclonal antibodies to poly-ADP-ribose polymerase (PARP) clone C2-10, cleaved PARP clone F21-852, BCL-X L , XIAP, (BD Bioscience), cyclin E (Santa Cruz), and GAPDH clone 6C6 (Abcam, Inc, Cambridge, MA).
Cell lines and culture
The MCF-7 and BT-474 cell lines were obtained from the ATCC (Manassas, VA) and maintained in DMEM:F12 (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum in the presence of 5% CO 2 at 37°C. Cells were routinely tested for Mycoplasma infection using a commercially available kit (Invitrogen, Carlsbad, CA).
Measurement of intracellular nucleoside triphosphate by HPLC
Perchloric acid was used to extract nucleotides from MCF-7 and BT-474 cells treated with 10 lM 8-Cl-Ado, and neutralized extracts were analyzed using HPLC (Waters 600E System Controller; Waters Corp., Milford, MA, USA) as described previously [17] . The column eluate was monitored using UV absorption at 256 nm, and the nucleoside triphosphates were quantitated using electronic integration with reference to external standards. 8-Cl-ATP was identified by comparing its retention profile and absorption spectrum with those of an authentic standard.
Inhibition of RNA synthesis MCF-7 and BT-474 cells were incubated with 10 lM 8-ClAdo for up to 12 h with the addition of 2 lCi/ml [ 3 H]uridine 30 min prior to harvesting. Acid-insoluble cellular material was retained on multiscreen-GV filters (Millipore Corp., Bedford, MA) as described [27] . The radioactivity on the filters was measured by scintillation counting and expressed as the percentage of control (untreated) value of cells. All statistical and regression analyses were determined using GraphPad Prism (GraphPad Software, Inc., San Diego, CA).
Growth inhibition analysis
For the MTS assay, 600 MCF-7 cells or 2,000 BT-474 cells were plated in 100-ll FBS supplemented media per well of a 96-well plate. Cells were grown for 5 days, and 8-Cl-Ado was added sequentially allowing all time points to be assayed simultaneously using AQueous OneSolution (Promega, Madison, WI) as per the manufacturer's instructions. Each time point in an individual experiment was assayed in triplicate and the experiment was performed in triplicate. The results are presented as a percentage of the untreated cells.
Colony formation assay
One thousand exponentially growing MCF-7 cells were plated in triplicate into 6-well dishes. The cells were allowed to attach for 24 h and were then exposed to 8-ClAdo for 3 days before being washed with PBS (37°C) and cultured in fresh medium for 14 days. Colonies of 50 cells were counted under a dissecting microscope. The experiments were performed in triplicates.
Flow cytometry MCF-7 and BT-474 cells were incubated with 10 lM 8-ClAdo for the indicated times. The cell cycle distribution and the annexin V and propidium iodide labeling of the cells were determined, respectively, as described in [21] and [9] . All flow cytometry analysis was performed using a Becton Dickinson FACSCalibur flow cytometer (San Jose, CA, USA).
Expression analysis
Exponentially growing cells were treated with 10-lM 8-ClAdo for various amounts of times, and the RNA was isolated with the RNeasy Mini kit (Qiagen S.A., Courtabeuf, France) in duplicate. The gene expression levels were measured on an ABI prism 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) using one-step real-time TaqMan RT-PCR as described [29] . The CCNE1 Taqman primers and probes (Sigma GenoSys, Woodlands, TX) were designed with PrimerExpress software (Applied Biosystems) and are as follows: Forward and reverse primers 5 0 -TCGCTGATGAAGATGCAC-ACA-3 0 and 5 0 -TTCTTTGCTCGGGCTTTGTC-3 0 , Taqman probe 5 0 -6FAM-AGCAAATCCAAGCTGTCTCTG TGGGTCTGTAT-BHQ1-3 0 . Each RNA sample was assayed in triplicate, and the results are presented as a percentage of the CCNE1 expression level in untreated cells. Western blot analysis using an Odyssey Infrared Imaging System (LI-COR Biosciences) was performed as described [29] .
Results
Time-dependent metabolism of 8-Cl-Ado in breast cancer cells
Typically, DNA-directed nucleoside analogs are not as effective in the treatment of solid tumors when compared to hematological malignancies. This is primarily due to the dependency of these analogs on deoxycytidine kinase for their conversion to an active metabolite, which is expressed at low levels in solid tumors [44, 45] . Previously, we have shown that 8-Cl-Ado (Fig. 1a) is cytotoxic to primary chronic lymphocytic leukemia cells [17] and multiple myeloma cell lines [23] and that 8-Cl-Ado cytotoxicity is dependent on its metabolism to its triphosphate by adenosine kinase [21] . Unlike deoxycytidine kinase, the expression of adenosine kinase is more ubiquitous and is relatively abundant in breast cancer cells [46] . This suggests that in these cells, 8-Cl-Ado would be readily metabolized to its active triphosphate form. To address this question, MCF-7 and BT-474 cells were treated with 10 lM 8-Cl-Ado for various times and perchloric acid extracts were analyzed using HPLC. In both the MCF-7 and the BT-474 cells, there was a rapid time-dependent increase in the intracellular level of the active metabolite, 8-Cl-ATP, (Fig. 1b, c) with the majority of the accumulation occurring in the first 4 h of treatment and by 6 h reached its plateau of *100 and *300 lM, respectively. Concomitantly, there was a steady decline in the level of endogenous ATP, which reached *40 and *60% of the initial control levels (MCF-7 = 340 lM and BT-474 = 1,575 lM) by 12 h (Fig. 1b, c) .
Effect of 8-Cl-ATP on RNA synthesis Since 8-Cl-ATP is an analog of ATP, we investigated whether it had any effect on RNA synthesis. To determine the relative amount of RNA synthesis, cells were incubated with 10 lM 8-Cl-Ado for the indicated times; however,
during the last 30 min of incubation, radiolabeled uridine was added to the medium. The level of radiolabeled uridine incorporated into RNA was then compared at each time point to untreated control cells. The results indicate that there was a time-dependent decline in RNA synthesis resulting in a 50% decrease by 24 h (Fig. 2a) .
Previously we showed that 8-Cl-ATP is able to incorporate into RNA and terminate transcription [27] , while the decrease in ATP should also affect the cells' ability to synthesize RNA. If the RNA synthesis inhibition is dependent on one or both of these, then there should be a relationship with the accumulation of 8-Cl-ATP and/or the cellular level of ATP. To determine this, a comparison of the percent inhibition of RNA synthesis to 8-Cl-ATP concentration was made (Fig. 2b) . There was a strong linear relationship between inhibition of RNA synthesis and 8-Cl-ATP accumulation in MCF-7 (r 2 = 0.75; p \ 0.0001) and BT-474 cells (r 2 = 0.80; p \ 0.0001). This indicates that the inhibition of RNA synthesis is dependent on the accumulation of 8-Cl-ATP. Additionally, because 8-Cl-ATP may act competitively against ATP for use during transcription, we examined the ratio of 8-Cl-ATP to ATP over time (Fig. 2c) as well as the relationship of this ratio to RNA synthesis inhibition (Fig. 2d) . The results showed that inhibition attained a maximum as the ratio of 8-Cl-ATP:ATP reached *0.5. Moreover, there was an exponential association between this ratio and RNA synthesis inhibition in MCF-7 (r 2 = 0.83) and BT-474 (r 2 = 0.79) cells, resembling a pseudo first-order enzyme inhibition reaction. This suggests that the ratio of 8-Cl-ATP:ATP plays an important role in RNA synthesis inhibition.
8-Cl-Ado inhibits cell growth and/or survival
The growth inhibitory effects of 8-Cl-Ado have been reported in lung [26] , colon [25, 47] , glioma [18, 20] , and malignant hematopoietic cell lines [17, 21, 23, 24, 48] . To investigate the growth inhibitory effects of 8-Cl-Ado on breast cancer cells, MCF-7 and BT-474 cells were incubated with various concentrations of 8-Cl-Ado (0.1-100 lM) for 5 days. At the end of the incubation time, growth inhibition was measured using the MTS cell titer assay. We found that growth was inhibited by as little as 0.1 lM 8-Cl-Ado in both cell lines (Fig. 3a) with an IC 50 for growth inhibition of 0.3 and 0.55 lM in the BT-474 and MCF-7 cells, respectively. To examine the kinetics of the growth inhibitory activities of 8-Cl-Ado, the cells were treated with 10 lM 8-Cl-Ado for various times and again measured using the MTS assay. Within 1 day of treatment, the growth of both breast cancer cells was inhibited. The kinetics of the inhibition were virtually identical between the MCF-7 and BT-474 cells and reached *90% inhibition by day 5. These results indicate that the effects of 8-Cl-Ado on the growth of MCF-7 and BT-474 cells are both dose-and time-dependent.
8-Cl-Ado does not alter cell cycle progression
To determine whether the growth inhibition of 8-Cl-Ado is due to cytostatic effects, exponentially growing MCF-7 and BT-474 cells were treated with 10 lM 8-Cl-Ado for various times, and their cell cycle profile was assessed using flow cytometry. In untreated MCF-7 cells, the average percentage of cells in G 1 , S, or G 2 /M phase was 62, 14, and 24%, respectively (Fig. 4a) . During the 3-day incubation, there were no statistically significant changes in any phase of the cell cycle. In untreated BT-474 cells, the average percentages in G 1 , S, and G 2 /M phase were 71, 11, and 18%, respectively (Fig. 4b) . Similar to the MCF-7 cells, there were no significant changes in G 1 or S phase of the cell cycle during the 3-day incubation. There was a statistically significant decrease in the percentage of cells in G 2 /M phase during this time period, 17.0-10.4% (p \ 0.05), which can be attributed to an increase in the subG 1 fraction of cells. Because the 8-Cl-Ado treatment of the breast cancer cells did not result in an accumulation of cells in any particular phase of the cell cycle, this suggests that the growth inhibition seen in Fig. 3 was not attributable to cytostatic growth; but more likely to loss of cell viability.
8-Cl-Ado is cytotoxic to breast cancer cells
To determine whether the effects of 8-Cl-Ado on breast cancer cells are associated with a decrease in cellular reproductive viability, clonogenicity assays were performed in MCF-7 cells. The results showed that 8-Cl-Ado significantly decreased clonogenic viability in a dose-dependent manner (IC 50 = 0.75 lM) (Fig. 5a ). At concentrations of 10 lM 8-Cl-Ado, clonogenic viability was inhibited by [85% and reached *95% inhibition with 100 lM. To ascertain that the loss in viability was due to an apoptotic response to 8-Cl-Ado treatment, the cells were examined for evidence of PARP cleavage using western blot analysis. Within 2 days of 10 lM 8-Cl-Ado treatment, PARP cleavage was readily detected in both cell lines (Fig. 5b) . Likewise, flow cytometry analysis of both cell lines treated with 10 lM 8-Cl-Ado showed that there was an induction of annexin V and/or propidium iodine-positive cells within 1 day of treatment (Fig. 5c) . These experiments establish that the growth inhibition associated with 8-Cl-Ado is due to a loss in cell viability due at least in part with an induction of apoptosis.
8-Cl-Ado inhibits cyclin E expression
Since therapeutic agents targeting cyclin E would be advantageous for the treatment of breast cancer and because CCNE1 mRNA is rapidly turned over (half-life as (Fig. 6a ) and continued to decrease up to *60% by 24 h. Additionally, a block in CCNE1 mRNA synthesis would be expected to instigate a decrease in cyclin E protein levels as it also has a short half-life [43] . To determine this, BT-474 and MCF-7 cells were treated with 10 lM 8-ClAdo and the levels of cyclin E were measured using immunoblot analysis. The analysis revealed that both the full-length 50-kDa cyclin E and the *40-kDa LMW cyclin E isoform levels were diminished in these cells after 8-ClAdo treatment (Fig. 6a) . Overall, these results demonstrate To determine whether 8-Cl-Ado-induced cytotoxicity was due to the depletion of an anti-apoptotic factor, the levels of MCL-1, BCL-2, BCL-X L , survivin, and XIAP were assessed in MCF-7 and BT-474 cells using western blot analysis after 24-h treatment with increasing dosage of 8-Cl-Ado. Interestingly, the expression of these anti-apoptotic genes did not significantly change after 8-Cl-Ado treatment (Fig. 7a, b) . Thus, 8-Cl-Ado-induced cytotoxicity does not appear to involve the depletion of any of these five survival factors but is likely through the loss of another factor(s) required for breast cancer cell survival.
Discussion
We show that 8-Cl-Ado has significant in vitro activity against breast cancer cells as it inhibits the growth and survival of MCF-7 and BT-474 cells when measured using MTS (Fig. 3 ) and clonogenetic survival (Fig. 5a) assays. This is due, at least in part, to an induction of apoptosis as determined using PARP cleavage analysis and annexin V staining (Fig. 5b, c) but not to any blocks in the progression of the cell cycle (Fig. 4) . Therefore, these results indicate that in breast cancer cells 8-Cl-Ado is primarily cytotoxic as opposed to cytostatic. During treatment, 8-Cl-Ado is taken up by the cells and is phosphorylated to its cytotoxic moiety, 8-Cl-ATP (Fig. 1b) while concomitantly diminishing the endogenous ATP pool (Fig. 1c) . Although the exact mechanism of 8-Cl-Ado-mediated cell death in these cells is not yet elucidated, the depletion of cellular ATP pool is expected to be a contributing factor as depletion of greater than 70% of the ATP levels in MCF-7 cells has been shown to inhibit clonogenic survival [49] and induce apoptosis [50] . A key contributor to the drug's cytotoxic activity likely involves 8-Cl-Ado-mediated inhibition of RNA synthesis as this may lead to depletion of specific transcript(s) required for tumor cell survival. Both the accumulation of 8-Cl-ATP and the decrease in the cellular ATP pool may play a role in the inhibition of RNA synthesis. ATP is not only a substrate for RNA polymerases, but it also promotes activation of these enzymes. We have found that 8-Cl-ATP is a substrate for all three human RNA polymerases, in particular RNA polymerase II, which leads to incorporation of the analog into the RNA chain, prematurely terminating transcription [27] . Furthermore, 8-Cl-ATP incorporation inhibits polyadenylation, a step required for synthesis and stability of the majority of mRNA transcripts [28] . These actions lead to a greater inhibition of mRNA transcription when compared to other RNA species. In breast cancer cells, we have found a strong linear relationship between inhibition of RNA synthesis and 8-Cl-ATP accumulation, while there was an exponential association with the 8-Cl-ATP:ATP ratio (Fig. 2d) . These results suggest that the 8-Cl-ATP:ATP ratio may be a key inhibitor of RNA synthesis in these cells.
The development of agents capable of targeting cyclin E is highly desirable for the treatment of breast cancer [51] as well as for other types of tumors with dysregulated cyclin E [52] [53] [54] . Deregulation of cyclin E and its LMW isoforms [30, 31] induces chromosome instability [34] [35] [36] and promotes breast cancer tumorigenesis and progression. Additionally, high expression levels of cyclin E isoforms have been associated with a poorer prognosis [37, 38] and resistance to hormone-directed therapies [34] . We have shown that 8-Cl-Ado treatment diminishes cyclin E levels in breast cancer cells (Fig. 6) ; thus, is an effective agent for targeting cyclin E. In contrast, the expression of several small survival factors was not inhibited by 8-Cl-Ado in these cells (Fig. 7) . Similar results were also seen in [29] . The reason for this is not known but possibly indicates that in addition to the turn-over rate, transcript size may also play an important role in 8-Cl-Ado-mediated transcription repression.
In conclusion, our data demonstrate that 8-Cl-Ado was effectively taken up, converted to its cytotoxic metabolite, 8-Cl-ATP, and depleted the endogenous ATP levels in breast cancer cells. This in turn leads to an inhibition of both RNA synthesis and cyclin E expression with the final outcome being loss of the tumor cell survival. This cytotoxic effect indicates that the analog may be an effective agent for the treatment of breast cancer. Additionally, because RNA-directed therapeutic agents exploit tumor cells' dependency or addiction [5, 7, 8 ] on short-lived oncogenes, growth regulators, and survival factors, 8-ClAdo is likely to alter the expression of a yet to be determined gene required for the survival of these cells.
